



HOKKAIDO UNIVERSITY

Title	Challenges in the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy in the young
Author(s)	Yamazawa, Hirokuni; Takeda, Atsuhito; Izumi, Gaku
Citation	Cardiology in the young, 32(1), 156-157 https://doi.org/10.1017/S1047951121002584
Issue Date	2022-01
Doc URL	https://hdl.handle.net/2115/86871
Rights	This article has been published in a revised form in Cardiology in the Young http://doi.org/10.1017/S1047951121002584 . This version is free to view and download for private research and study only. Not for re-distribution or re-use. © copyright holder
Type	journal article
File Information	CY 32(1) 156-157.pdf



Challenges in the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy in the young

Hirokuni Yamazawa, Atsuhito Takeda, Gaku Izumi

Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan

Corresponding author

Hirokuni Yamazawa, M.D., Ph.D.

Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine

Hokkaido University

North 15 West 7, Kitaku Sapporo, Postal code 060-8638 Japan

Tel: 81 11 706 5954

Fax: 81 11 706 7898

E-mail: yamazawa@med.hokudai.ac.jp

ORCID: 0000-0002-9257-5623

Abstract

A case of hypertrophic cardiomyopathy in the transition from childhood to adulthood, which was low-risk by the conventional risk assessment model, medium-risk by the adult risk prediction model, and high-risk by the pediatric risk prediction model was inserted an implantable cardioverter-defibrillator. Three years post-implantation, the patient was resuscitated with an appropriate discharge of cardioverter-defibrillator.

Keywords

implantable cardioverter-defibrillator, hypertrophic cardiomyopathy, late gadolinium enhancement-MRI, primary prevention of sudden cardiac death, risk prediction model

Introduction

Hypertrophic cardiomyopathy is a well-known cause of sudden cardiac death in the young. Therefore, the primary prevention of sudden cardiac death is imperative. It is important to make a clear distinction between candidates and non-candidates for the primary prevention of sudden cardiac death. The risk of sudden cardiac death can now be calculated probabilistically using risk calculation models for adults and children. However, it remains a challenge to distinguish between candidates and non-candidates for the primary prevention of sudden cardiac death. Herein, we present a case of hypertrophic cardiomyopathy in the transition from childhood to adulthood where we contemplated inserting an implantable cardioverter-defibrillator.

Case Report

The patient was a 20-year-old male with hypertrophic cardiomyopathy whose electrocardiogram showed an abnormal T-wave. He was diagnosed at 6 years of age by echocardiography. A p.Ala63Val mutation in the Tropomyosin alpha-1 (TPM1) gene, which is one of the sarcomere genes, was detected through genetic analysis of the patient. The patient's family history revealed that his elder brother, father, and grandmother also had hypertrophic cardiomyopathy and his paternal uncle died suddenly; however, it is unclear whether the death was associated with hypertrophic cardiomyopathy. The elder brother had an episode of syncope at 18 years of age while running, but was resuscitated using an automated external defibrillator by a bystander.

Before the insertion of the implantable cardioverter-defibrillator, the patient had none of the five major classical risk factors (non-sustained ventricular tachycardia, a maximum left ventricular wall thickness ≥ 30 mm or a Z-score ≥ 6 , family history of sudden cardiac death associated with hypertrophic cardiomyopathy, unexplained syncope, and abnormal blood pressure response to exercise) associated with sudden cardiac death¹, except the elder brother's near-miss event, which was considered a possible risk factor. Thus, the patient was deemed a low-risk case. In contrast, the patient's late gadolinium enhancement-MRI results showed an increasing late enhancement area of 1% to 16% of left ventricular mass over two years between ages 10 and 12. We considered this an indication of increased risk. However, to reduce the probability of complications due to implantable cardioverter-defibrillator insertion, we decided to wait until growth slowed down. When the patient turned 16 years of age, we applied the risk prediction model from the 2014 European Society of Cardiology for hypertrophic cardiomyopathy over 16 years of age at the time², and the risk of sudden cardiac death was assessed at 4.8 % per 5 years, which means that implantable cardioverter-defibrillator insertion was still an option. Ultimately, although aggressive conclusion that should be inserted an implantable defibrillator was not obtained, we obtained informed consent from the patient and his family and implantable cardioverter-defibrillator insertion was planned for the primary prevention of sudden cardiac death³. The patient underwent the transvenous insertion of a dual chamber implantable cardioverter-defibrillator at 17 years of age after achieving maximum

growth in height. The device was programmed with two zones; a ventricular fibrillation zone with the lower detection rate of ≥ 220 bpm and a ventricular tachycardia zone with a rate ≥ 180 bpm. In the ventricular tachycardia zone, two sequences of anti-tachycardia pacings and subsequent shocks were included. Three years later, the patient experienced a syncopal episode due to a ventricular tachycardia attack when he was having lunch at the university cafeteria. He had a sinus rhythm of 94 bpm before this episode. Initially, monomorphic ventricular tachycardia with rates between 160 and 180 bpm occurred and sustained for approximately 4 minutes. Subsequently, it accelerated above 180 bpm and anti-tachycardia pacing therapies were given, which failed to terminate ventricular tachycardia. 21 J shock was then delivered, which terminated the episode. However, polymorphic ventricular tachycardia with a rate of about 200 bpm recurred immediately, and 41 J shock was delivered, which restored sinus rhythm.

Discussion

In this case, the necessity of inserting the implantable cardioverter-defibrillator could not be confirmed before the procedure. Before the publication of the 2014 European Society of Cardiologist risk prediction model, this case was assessed as low-risk, and inadequate evaluation was attributed to the lack of weighting of risk factors. Since its publication in 2014, risk factors have been weighted. However, this still cannot be applied to patients under 16 years of age.

Ultimately, evaluating our patient at 16 years of age using this model was not sufficiently valid. It has been known that the risk prediction model has a lower sensitivity and, as a result, misidentified patients who later experienced a sudden cardiac death event as low risk. In fact, in the American Heart Association Scientific Sessions 2019, the Tufts hypertrophic cardiomyopathy institute reported a sensitivity of 50% when using the risk prediction model⁴. Moreover, a validation study of the risk prediction model in adult Japanese cases showed an even lower sensitivity of 32% than Western cases⁵. In our case, implantable cardioverter-defibrillator insertion was considered based on changes in the findings of late gadolinium enhancement-MRI. However, after the procedure in our patient, two new pediatric risk prediction models were published. Based on the risk prediction model proposed by Norrish et al.⁶, the risk of sudden cardiac death in our patient at 16 years was assessed at 9.4 % per 5 years, which is beyond the indication line for implantable cardioverter-defibrillator insertion. Furthermore, applying the latest risk prediction model applicable to those under the age of 18 reported by Anastasia et al.⁷, the risk at the age of 16 was 8.9 % per 5 years, which is also beyond the indication line for implantable cardioverter-defibrillator insertion. Afterthought, it can be said that the new pediatric risk prediction model was able to perform a valid risk assessment in this case.

Based on the above, in the case of hypertrophic cardiomyopathy in the transition from childhood to adulthood, if the risk prediction model is within the age range that can be used, not only the 2014

European Society of Cardiology risk prediction model but also the recent pediatric risk prediction models should be used to consider the indications for implantable cardioverter-defibrillator insertion. For this purpose, it is necessary to hurry the validation study in Japanese cases.

Conclusion

There are still challenges in assessing the risk of sudden cardiac death in hypertrophic cardiomyopathy in the young. Although new risk assessment models are promising, robust validation of these new risk assessment models in Japanese cases is needed.

Acknowledgements: We would like to thank Seema Mital, M.D., of the Hospital for Sick Children, Toronto, Ontario, Canada, for calculating with the latest pediatric risk prediction model and Masaya Watanabe, M.D., Ph.D., of the Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan, for proofreading the text regarding the appropriate discharge of the implantable cardioverter-defibrillator.

Financial Support: This research received no specific grant from any funding agency or commercial or not-for-profit sectors.

Conflicts of Interest: None.

References

- 1 Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2011; 58: e212-260.
- 2 O'Mahony C, Jichi F, Pavlou M et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). *Eur Heart J* 2014; 35: 2010-2020.
- 3 Yamazawa H, Takeda A, Takei K, Furukawa T. Primary prevention of sudden cardiac death in a low-risk child with familial hypertrophic cardiomyopathy: the role of cardiac magnetic resonance imaging. *Clin Res Cardiol* 2014; 103: 75-77.
- 4 Sridharan A, Maron BJ, Madias C et al. Abstract 12090: Modern Treatments Can Abolish Mortality in Pediatric Patients With Hypertrophic Cardiomyopathy. *Circulation* 2019; 140: A12090-A12090.
- 5 Nakagawa S, Okada A, Nishimura K et al. Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model Among Various Phenotypes in Japanese Patients With Hypertrophic Cardiomyopathy. *The American Journal of Cardiology* 2018; 122: 1939-1946.
- 6 Norrish G, Ding T, Field E et al. Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). *JAMA Cardiol* 2019.
- 7 Miron A, Lafreniere-Roula M, Steve Fan CP et al. A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. *Circulation* 2020; 142: 217-229.

Fig 1a




Fig 1b




Fig 2a




Fig 2b

